https://orcid.org/0000-0002-7822-8852
References
- Jackson SP. Arterial thrombosis–insidious, unpredictable and deadly. Nat Med. 2011;17:1423–1436.
- Parker WA, Storey RF. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart. 2016;102:783–789.
- Parker WA, Bhatt DL, Prats J, et al. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost. 2017;117:1093–1100.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339.
- Caroff E, Meyer E, Treiber A, et al. Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation. Bioorg Med Chem Lett. 2014;24:4323–4331.
- Ufer M, Huynh C, van Lier JJ, et al. Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects. Xenobiotica. 2020;50:427–434.
- Caroff E, Hubler F, Meyer E, et al. 4-((R)-2-{[6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}- 3-phosphonopropionyl)piperazine-1-carboxylic acid butyl ester (ACT-246475) and its prodrug (ACT-281959), a novel P2Y12 receptor antagonist with a wider therapeutic window in the rat than clopidogrel. J Med Chem. 2015;58:9133–9153.
- Rey M, Kramberg M, Hess P, et al. The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. Pharmacol Res Perspect. 2017;5:e00338.
- Baldoni D, Bruderer S, Krause A, et al. A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial. Clin Drug Investig. 2014;34:807–818.
- Juif PE, Boehler M, Dobrow M, et al. Clinical pharmacology of the reversible and potent P2Y12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects. J Clin Pharmacol. 2019;59:123–130.
- Storey RF, Gurbel PA, Ten Berg J, et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J. 2019:ehz807. doi: 10.1093/eurheartj/ehz807.
- Sinnaeve PR, Fahrni G, Schelfaut D, et al. Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: a randomised open-label phase 2 study. Eur Heart J. 2019;40(suppl 1):ehz746.0078.
- Zwart B, Yazdani M, Ow KW, et al. Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets. 2020;31:174–178.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–260.
- Storey RF, Gurbel PA, James S, et al. Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients. Eur Heart J. 2019;40(suppl 1):ehz748.0136.
- Kheiri B, Osman M, Abdalla A, et al. Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2019;47:233–247.
- Judge HM, Buckland RJ, Jakubowski JA, et al. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets. 2016;27:191–195.